Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund
Fund managers: Bhavesh Jain; Manasi Jalgaonkar; Amit Vora
Benchmark: MSCI India Domestic & World Healthcare 45 Index · Riskometer: Very High · SEBI category, as filed: Fund of funds investing overseas ·
Source: AMFI scheme summary document
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Direct Plan - Growth
Source: AMFI
The scheme's yearly running cost as a % of its assets, taken out of the NAV a little each day. A regular plan costs more: it pays a distributor's commission.
Category median: direct 0.39 %, regular 0.93 % (284 schemes) · Regular costs ₹540 more a year per ₹1 lakh
Of this, the base expense ratio, the part SEBI caps: direct 0.44 %, regular 0.90 %. The rest is brokerage, transaction costs and statutory levies such as GST and STT, as AMFI's file lists them.
A year, as of 21 Nov 2026. Source: AMFI · Glossary: TER
| Period | Direct plan | Regular plan | Benchmark, as published by AMFI MSCI India Domestic & World Healthcare 45 Index |
|---|---|---|---|
| 1 year | +20.24 % | +19.58 % | — |
| 3 years | +20.49 % | +19.84 % | — |
| 5 years | +15.34 % | +14.70 % | — |
| Since launch | +16.89 % | +16.23 % | — |
Past performance may not be sustained in future.
As AMFI's fund performance report prints them for "Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund"; this site computes no benchmark figure of its own.
How it is computed: NAV to NAV
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Direct Plan - Growth: these run to the newest NAV stored (20 Nov 2026) and are computed here from AMFI's NAV files; AMFI's figures above run to 19 Nov 2026, so the two differ by the days in between.
| Period | Return | From | To |
|---|---|---|---|
| 1 year | +20.97 % in total | 20 Nov 2025 · NAV ₹21.3973 | 20 Nov 2026 · NAV ₹25.8849 |
| 3 years | +20.51 % a year, compounded | 20 Nov 2023 · NAV ₹14.7822 | 20 Nov 2026 · NAV ₹25.8849 |
| 5 years | +15.42 % a year, compounded | 18 Nov 2021 · NAV ₹12.6230 | 20 Nov 2026 · NAV ₹25.8849 |
| Since first NAV | +17.03 % a year, compounded | 2 Nov 2020 · NAV ₹9.9925 | 20 Nov 2026 · NAV ₹25.8849 |
Source: AMFI NAV files (plan code 148555). How to read Report a wrong number
Not enough NAV history stored yet for rolling returns and a monthly SIP.
Tracking error and tracking difference
index fund / ETF · as published by AMFI
| Tracking difference, Oct 2026 | Direct plan | Regular plan |
|---|---|---|
| 1 year | −0.31 % | −0.97 % |
| 3 years | −0.49 % | −1.15 % |
| 5 years | −0.47 % | −1.10 % |
| Since launch | −0.32 % | −0.98 % |
As AMFI publishes them against MSCI India Domestic & World Healthcare 45 Index. Source: AMFI tracking error and tracking difference. How to read
IDCW (dividend) history
0 declarations · as of 2 Nov 2026 · Source: AMFI
IDCW (formerly "dividend") declared per unit of each IDCW plan, as AMFI lists it.
Calendar-year returns, Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Direct Plan - Growth
NAV to NAV · Source: AMFI
| Year | Return | From | To |
|---|---|---|---|
| 2025 | +5.48 % | 31 Dec 2024 · NAV ₹20.3199 | 31 Dec 2025 · NAV ₹21.4330 |
| 2024 | +29.57 % | 29 Dec 2023 · NAV ₹15.6827 | 31 Dec 2024 · NAV ₹20.3199 |
| 2023 | +25.11 % | 30 Dec 2022 · NAV ₹12.5354 | 29 Dec 2023 · NAV ₹15.6827 |
| 2022 | −4.75 % | 31 Dec 2021 · NAV ₹13.1610 | 30 Dec 2022 · NAV ₹12.5354 |
| 2021 | +18.78 % | 31 Dec 2020 · NAV ₹11.0800 | 31 Dec 2021 · NAV ₹13.1610 |
Past performance may not be sustained in future.
Change in the plan's NAV over each calendar year, last NAV to last NAV. Source: AMFI NAV files. How to read
Embed this card
Copy this into any web page. The image carries its source, date and a link back; it is redrawn each night.
- 27 Oct 2026 · TER change: Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund: AMFI TER file of 27 Oct 2026: direct plan 0.56% (was 0.55%); previous file 26 Oct 2026
From AMFI's own files (scheme summary documents, NAV history, TER), as they stood on the day shown.
All schemes of Edelweiss Mutual Fund →
Mutual fund investments are subject to market risks; read all scheme related documents carefully.